Humacyte, Inc. (HUMA)

NMS – Real Time Price. Currency in USD

0.71

+0.09 (14.29%)

At close: Jun 26, 2026, 4:00 PM EDT

0.74

+0.04 (5.12%)

After-hours: Jun 26, 2026, 7:58 PM EDT

16.06.2026

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.

16.06.2026

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript

15.06.2026

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

15.06.2026

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – – Company to hold investor event today, June 15 th , at 5:00 p.m. ET – DURHAM, N.C.

11.06.2026

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

10.06.2026

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

10.06.2026

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 -

Videos

No Data

There is no data to display

Press releases

15.06.2026

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

11.06.2026

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

10.06.2026

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

10.06.2026

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 -

Humacyte, Inc. (HUMA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Humacyte, Inc. (HUMA)

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Videos

No Data

Press releases

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Videos

No Data

Press releases

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Search stocks

Humacyte, Inc. (HUMA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Humacyte, Inc. (HUMA)

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Videos

No Data

Press releases

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Videos

No Data

Press releases

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients